Innovation in the Race to Develop COVID-19 Vaccines

Vaccines are considered to be one of the greatest public health achievements of the last century, so when the COVID-19 pandemic brought the world to a stop, all energies were focused on bringing a vaccine to market.

With multiple vaccines now approved and being manufactured in record time, we celebrate this accelerated pace of development in the field. Exploring the different vaccine technologies to understand their mode of action, benefits, risks, and potential real-life impact on protection. The challenges in manufacturing enough doses to vaccinate the world and the potential impact the WTO’s IP waiver proposal will have on future innovation.

Discussion Points:

• Vaccine Science: Two Centuries of Continuous Research, Improvements, and Achievements
• Future Potential of mRNA
• Where are the facilities equipped for these new molecule types? What problems are arising and how is the industry working to fix them?
• Vaccinating the world, a look at WTO’s proposed IP waiver and what it could mean for future innovation

This session was originally broadcast live as part of CPhI North America 2021.

Speakers Include:

• Leonard Friedland, Vice President, Director Scientific Affairs and Public Health, GSK Vaccines
• Fiona Barry, Associate Editor, Global Data
• Dr Fintan Walton, CEO of PharmaVentures

△ Legitimate business purposes include contacting me regarding PharmaVentures’ services, commercial opportunities in M&A, Licensing, Fundraising or similar on behalf of their clients or sending me marketing material related to relevant third-party events, products and services.

For further information on how PharmaVentures processes your data, please view our Privacy page.